Search PubMed⌕ Search

Biomedical subjects

U Tebbe

Publications and source records attributed to U Tebbe.

At least 127 records · Page 7Linked to original sources
PubMed1990

[Coronary angioplasty with the implantation of a vascular support (stent)].

Coronary angiography in a 55-year-old man with coronary heart disease and typical physical activity-induced angina revealed a subtotal stenosis in the middle third of the right coronary artery while left ventricular function was normal. Percutaneous transluminal coronary angioplasty (PTCA) was performed in January 1989, achieving a residual stenosis of less than 50%. However, restenosis of more than 90% developed within six months, necessitating another PTCA, followed immediately by implantation of a metal (Palmaz-Schatz) stent in the stenotic area. No stenosis was demonstrable afterwards. Maintenance medication with anticoagulants (phenprocoumon) and platelet-function inhibitors (aspirin and dipyridamole) was instituted and repeat angiography three months later demonstrated good dilatation results without any restenosis.

Angioplasty, Balloon, Coronary↗
PubMed1990

[Thrombolysis in resuscitated patients with pulmonary embolism].

A retrospective analysis is presented of data from 17 patients with proven pulmonary embolism (10 women, 7 men, mean age 50.8 [18-76] years) who had received short-term high dosage thrombolytic therapy shortly before or after (less than 24 h) undergoing mechanical resuscitation. The mean duration of resuscitation was 76 (20-160) minutes. Two patients had already been resuscitated half an hour and one hour, respectively, before the commencement of thrombolysis. In nine other patients thrombolysis was commenced during resuscitation. Hospital mortality in the latter group was amazingly low (four of nine patients died). In contrast, out of six patients who required resuscitation shortly after the commencement of thrombolysis, not one survived. Haemorrhagic complications occurred in four out of the 17 patients, but only in two were they directly attributable to the resuscitation: one female patient developed an extensive haematoma in the sternal region, and two days after resuscitation another female patient had a haemorrhage into the capsule of the liver during thrombolytic therapy which had been continued because of leg vein thrombosis. In the light of these results it seems justifiable, even on mere clinical suspicion of pulmonary embolism, to initiate short-term high dosage thrombolytic therapy during or after resuscitation.

Adolescent↗
PubMed1990

Embolic mononeuropathy in subacute bacterial endocarditis.

A 49-year-old man presented with temperature up to 39.5 degrees C, a sudden peroneal nerve lesion, and a cardiac murmur. The peroneal nerve lesion was likely caused by an embolic occlusion of an artery supplying the nerve. Until now, six cases of embolic mononeuropathy in endocarditis have been reported in the literature. Embolic mononeuropathy is a very rare manifestation of subacute bacterial endocarditis and quite often complicates, as do other more common embolic manifestations, the correct diagnosis.

Embolism↗
PubMed1990

Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure, and cardiac output in patients with heart failure.

Ketanserin is a selective serotonin2-receptor blocker and by this mechanism decreases peripheral resistance and blood pressure in hypertensives. We examined the hemodynamic effects of ketanserin during long-term treatment in patients with heart failure. Five male patients with coronary artery disease and heart failure (NYHA classes II-III) were treated with ketanserin (80 mg daily) for 12 months. Before treatment, after 4 weeks, and after 12 months treatment, a Swan-Ganz catheter was placed into the pulmonary artery and pulmonary wedge pressure, cardiac output, mean arterial pressure, and heart rate were measured at rest and on exertion. The pulmonary wedge pressure at rest decreased from 8 mmHg before to 6 mmHg after 4 weeks and 12 months treatment; on exertion, it decreased from 31 mmHg before treatment to 24 mmHg after 4 weeks treatment and to 21 mmHg after 12 months treatment. The mean arterial pressure also decreased at rest and on exertion after 4 weeks treatment as well as after 12 months treatment. Cardiac output increased slightly and heart rate was unaltered. No serious side effects occurred. Ketanserin could become an alternative vasodilator drug in the treatment of patients with heart failure.

Aged↗
PubMed1990

Transfemoral placement of the left ventricular assist device "Hemopump" during mechanical resuscitation.

The Hemopump is a new left-ventricular assist device (21 F diameter), which provides up to 3.5 L/min output after placement in the left ventricle via the femoral artery. We describe the first case in which the device was inserted during resuscitation. The patient developed untreatable sustained ventricular tachycardias/fibrillation 40 hours after coronary artery bypass grafting. After prolonged mechanical resuscitation (about 3 hours) as a last resort the Hemopump was inserted and rhythm and hemodynamics stabilized. In the following hours a decrease in aortic pressure pulsatility indicated, effective left ventricular support when the Hemopump was running. For short periods the patient had nonpulsatile aortic pressure wave forms, implying complete pump dependence. In this situation cardiac output was about 3.0 L/min, mean aortic pressure reached nearly 50 mmHg using high dosage of catecholamines. The patient remained pump-dependent and died due to untreatable ventricular fibrillation. There was no significant hemolysis during the 20 hours the Hemopump was running. Autopsy revealed no signs of thrombembolism, but intimal lesions of the A. iliaca and of the abdominal aorta with subsequent thrombus formation were demonstrated. In view of the experimentally proven benefit in cardiogenic shock and problems and risks caused by the insertion, future indications for clinical use of this new device are discussed.

Femoral Artery↗
PubMed1990

Controversial indications. Rationale for thrombolysis: later than 4-6 h from symptom onset, and in patients with smaller myocardial infarctions. The ISAM Study Group.

To evaluate the effect of late reperfusion of an infarct-related coronary artery on left ventricular (LV) function in the month after myocardial infarction (MI), findings from 386 patients in the Intravenous Streptokinase in Acute Myocardial Infarction (ISAM) trial were studied. All patients had a late peaking in the creatine kinase-MB serum time-activity curve, suggesting absence of early reperfusion. Significantly better LV function associated with patency of the infarct artery at angiography 1 month after the acute event confirmed the beneficial effect of reperfusion even if achieved beyond the time window for myocardial salvage. Thrombolysis commenced later than 4-6 h after symptom onset will be of benefit as long at it reopens infarct arteries more often and earlier than occurs spontaneously or from anticoagulation. The value of the size of the sum of ST-segment elevation (sigma ST increases) on admission ECG was evaluated from the total ISAM study population. The relation between sigma ST increases and final infarct size as well as mortality risk was highly significant. However, weak correlations largely limit the value of sigma ST increases to predict the outcome in an individual patient. Thus, whatever the relative beneficial effect in patients with smaller or larger MI may be, it would be unwarranted to withhold thrombolytic therapy from patients with smaller sigma ST increases on admission ECG.

Aged↗
PubMed1990

Intravenous streptokinase in acute myocardial infarction (I.S.A.M.): assessment of left ventricular function 1 and 7 months after infarction by radionuclide ventriculography.

I.S.A.M. was a prospective, placebo-controlled, double-blind multicentre trial of high-dose short-term intravenous streptokinase in acute myocardial infarction (AMI) within 6 h of the onset of symptoms. Determination of left ventricular ejection fraction (LVEF) by radionuclide ventriculography was performed 1 and 7 months after AMI in a subset of 192 patients at rest and, in 140 of them, also during exercise. Regional myocardial function was analysed in all 145 patients with neither a history of a previous myocardial infarction nor revascularization procedures or reinfarction within the 7-month follow-up period. One month after AMI, mean LVEF was higher in the streptokinase group in patients with anterior AMI (50 +/- 15% vs 42 +/- 16%, P = 0.013). This difference was more marked in the subgroup treated within 3 h (53 +/- 14% vs 42 +/- 15%, P = 0.004), whereas patients treated 3-6 h after the onset of symptoms did not differ from respective controls (41 +/- 16% vs 41 +/- 18%). In patients with inferior AMI, the difference in mean LVEF was small (57 +/- 11% vs 55 +/- 12%, P = 0.47). After anterior AMI benefit due to streptokinase therapy was preserved up to 7 months (52 +/- 14% vs 44 +/- 17%, P = 0.013). During exercise, the increase of mean LVEF was greater in the streptokinase group at both dates, especially 7 months after AMI (4.1 +/- 6.1% vs 1.2 +/- 6.3%, P = 0.015). In streptokinase-treated patients with anterior AMI, regional LVEF at rest was higher at both dates compared with controls, within the infarct zone as well as in remote myocardium. No treatment-control differences were demonstrable in patients with inferior AMI. During exercise, regional contractile reserve was better in the streptokinase group within the infarct zone as well as in remote myocardium, irrespective of the site of infarction. Thus, intravenous streptokinase within 3 h after the onset of AMI preserves global left ventricular function in anterior AMI over a period of at least 7 months. Intravenous streptokinase improves regional myocardial function within the infarct zone as well as in remote areas. In inferior AMI investigation solely at rest may underestimate the benefit of streptokinase therapy.

Aged↗
PubMed1990

Hemodynamic effects of nebivolol at rest and on exertion in patients with heart failure.

Nebivolol is a novel B-1-adrenoceptor-blocking drug with an unusual hemodynamic profile unlike classical B-blockers. In dogs and in healthy volunteers it decreases blood pressure and heart rate but improves left ventricular function. The authors studied 10 male patients with coronary artery disease and heart failure (ejection fraction mean = 46%). A Swan-Ganz catheter was placed into the pulmonary artery, and the mean blood pressure, the heart rate, the pulmonary artery pressure, the pulmonary wedge pressure, the right atrial pressure, the cardiac output, and the stroke volume were measured at rest and on exertion before and after seven days' treatment with oral nebivolol (5 mg/day). While the blood pressure and the heart rate decreased significantly, the pulmonary artery and wedge pressures, as well as the right atrial pressure and the cardiac output, did not change during treatment. The stroke volume increased significantly. The maintained cardiac output cannot be explained by any changes in preload or afterload; instead a positive inotropic mechanism must be assumed. Unlike other B-blockers it seems to be possible to treat patients with heart failure with nebivolol without causing the hemodynamic situation to deteriorate.

Adrenergic beta-Antagonists↗
PubMed1990

Prevention of an early re-occlusion after thrombolytic therapy of acute myocardial infarction by ketanserin.

A problem after successful thrombolytic therapy of acute myocardial infarction is the early occurrence of re-occlusions. An incidence between 10 and 30% is reported. All efforts made so far to reduce the re-occlusion rate using a variety of agents have been disappointing. In a pilot study 20 patients with acute myocardial infarction were treated, in whom a successful lytic therapy with urokinase or rt-PA was documented by means of coronary angiography 90 min after the beginning of treatment. Subsequently the patients were heparinised (thrombin time greater than 30 s), and in addition the selective serotonin-2 receptor-blocking agent ketanserin was given intravenously (4 mg/h). After 24 h the occurrence of early reocclusions was investigated by control angiography. None of the 20 patients showed reocclusions. The degree of stenosis in the infarcted vessel was 72% immediately after lytic therapy, and 68% after 24 h. These preliminary results may suggest a possible reduction in the re-occlusion rate after thrombolytic therapy with a combination of heparin and ketanserin.

Adult↗
PubMed1990

Serotonin antagonism in the treatment of cardiac insufficiency.

One approach in the therapy of cardiac insufficiency is the administration of vasodilator substances for afterload reduction. Ketanserin selectively blocks the serotonin-2 receptors and thus inhibits the vasoconstrictor effect of serotonin. A hypotensive action of ketanserin has been documented in several studies. In 10 patients with coronary heart disease and cardiac insufficiency we investigated the haemodynamic effects of ketanserin after 24 h of intravenous administration (4 mg/h) and after 4 weeks of oral therapy (80 mg/day). Five patients received ketanserin for 12 months and were then re-examined. The resting mean arterial pressure dropped from 97.1 to 89.3 mm Hg after intravenous administration (p less than 0.05) and to 89.3 mm Hg after 4 weeks of oral intake (p less than 0.05). The resting mean pulmonary arterial pressure dropped from 15.2 to 12.0 mm Hg after intravenous administration (p less than 0.05) and to 11.7 mm Hg after 4 weeks of oral ingestion (p less than 0.01). Under exercise the pressure dropped from 35.3 to 28.1 mm Hg after intravenous administration (p less than 0.0025) and to 29.9 mm Hg after 4 weeks of oral intake (p less than 0.0025). Heart rate and cardiac output did not show any significant differences. The measured values after 12 months (in 5 patients) did not differ significantly from those measured after 4 weeks. In view of its low side effect liability ketanserin could be used as an afterload-lowering agent in patients with cardiac insufficiency.

Administration, Oral↗
PubMed1989

[Intra-aortal balloon counterpulsation in acute myocardial infarction, ischemic left ventricle insufficiency and treatment refractory angina pectoris].

Intraaortic balloon counterpulsation (IABP) was employed between 1977 and 1988 in 132 patients (37 women and 95 men; mean age 60 +/- 9.9 years) with coronary heart disease. Indications for IABP were cardiogenic shock in 93, markedly impaired left ventricular function in 13, and treatment-refractory angina in 26. The hospital mortality rate among those patients in cardiogenic shock was 54%. The mortality rate among the 47 patients who had additional procedures (percutaneous transluminal coronary angioplasty or operation) was 40%, significantly lower than that in 46 patients without further procedure (67%). Complications of IABP occurred in 20% of patients (bleeding, vascular injury, ischaemia in the legs, embolism or infection). The complication rate was, however, reduced to 10% in the last few years by improvements in placement technique and materials. Introduction and placement of the balloon catheter is simple, rapid and reliable. The initially high success rate is particularly valuable for those patients in whom further therapeutic measures can be undertaken.

Adult↗
PubMed1989

Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator.

To improve further the patency rate of infarct-related coronary arteries, the following accelerated dosage regimen of recombinant tissue-type plasminogen activator (rt-PA) was administered to 80 patients with acute myocardial infarction of less than or equal to 6 h duration: 15 mg intravenous bolus, 50 mg infusion over 30 min and 35 mg infusion over the following 60 min. After coronary angiography at 90 min coronary angioplasty was performed in 16 patients and additional thrombolysis in 3 patients. Six patients were not included in the final angiographic analysis, mostly because of borderline ST segment elevations, in order to avoid overestimation of the efficacy of this dose regimen. Four of these had a patent infarct artery; no early angiogram was performed on two. Sixty minutes after the start of infusion, 54 (74%) of 73 patients had a patent infarct-related artery (Thrombolysis in Myocardial Infarction [TIMI] grade 2 or 3) as did 67 (91%) of 74 patients at 90 min. At 24 h, 61 (92.4%) of 66 patients showed a patent infarct artery. Recurrent myocardial ischemia was noted in 12 patients, 7 (9.4%) of whom experienced reinfarction during the hospital stay. Minor local bleeding complications were observed in 14 patients (17.5%). There were four in-hospital cardiac deaths; one patient who underwent additional thrombolysis for recurrent ischemia died from bleeding complications. These results show that a rapid infusion of 100 mg of rt-PA over 90 min yields a high early patency rate of the infarct-related artery without an increase in reocclusion rate and adverse reactions.

Adult↗
PubMed1989

Impact of late coronary artery reperfusion on left ventricular function one month after acute myocardial infarction (results from the ISAM study).

To evaluate the impact of late reperfusion of an infarct-related coronary artery on left ventricular (LV) function in the month after myocardial infarction, findings from 368 patients in the Intravenous Streptokinase in Myocardial Infarction study are presented. All patients had a late peaking in the creatine kinase-MB serum time-activity curve, suggesting absence of early reperfusion. Contrast angiography was performed 1 month after the acute event. The infarct-related coronary artery was patent in 74 of 116 (64%) streptokinase-treated patients and 141 of 252 (56%) patients treated with anticoagulant therapy (placebo group). In all baseline variables, including the actually developed enzymatic and electrocardiographic infarct sizes, there were no differences between the patent- or occluded-artery groups. A patent infarct artery 1 month after infarction was associated with significantly better LV function regardless of the vessel involved and whether or not patients had been treated with streptokinase. Ejection fraction in patients with patent versus occluded artery was 56 +/- 13 versus 50 +/- 14 (p less than 0.0005). Most benefit was noted in patients in whom the proximal left anterior descending coronary artery was affected: ejection fraction was 52 +/- 14 versus 36 +/- 12% (p less than 0.0005). Our data confirm that restoration of adequate flow through an infarct-related coronary artery beyond the time window for actual salvage of ischemic myocardium has a definite beneficial effect on LV function.

Aged↗
PubMed1989

Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction.

Recombinant tissue-type plasminogen activator (rt-PA) has hitherto been administered in acute myocardial infarction as an intravenous infusion with an initial bolus of about 10% of the total dose, both due to its short half-life and to avoid possible early reocclusions. A single-bolus dose would simplify the therapeutic regimen. Therefore, 20 patients with symptom duration of 125 +/- 58 minutes were given a single bolus of 50 mg of rt-PA over 2 minutes. Coronary angiography 60 minutes after the rt-PA bolus revealed a patent infarct-related artery in 15 of 20 patients (patency rate 75%, 95% confidence limits 51 to 91%). In the remaining patients, reperfusion was achieved by coronary angioplasty and intracoronary fibrinolysis; in 2 patients coronary artery bypass grafting was necessary. Control angiograms at 24 hours showed reocclusions in 4 of 18 patients. One woman died due to an intracranial hemorrhage 48 hours after the rt-PA bolus injection. Circulating fibrinogen decreased from 2.7 +/- 0.5 to 1.5 +/- 0.9 g/liter after 2 to 4 hours and reached the initial value within 24 hours. Pharmacokinetic parameters were obtained in 7 patients by measuring rt-PA antigen levels in multiple plasma samples. Mean peak rt-PA concentration was 9.8 +/- 3.6 micrograms/ml, total plasma clearance 476 +/- 148 ml/min and dominant half-life 4.8 +/- 1.0 minutes. Thus, rt-PA administered as a 50-mg single bolus appears to provide similar patency rates and shows similar kinetics in comparison with the conventional infusion regimen. Assessment of the incidence of bleeding complications requires further studies.

Adult↗
PubMed1989

[Balloon catheter arterial occlusion before high-risk splenectomy and nephrectomy].

Balloon catheter occlusion of the splenic or renal artery was undertaken in 10 patients (7 men and 3 women, aged 20-76 years) 30 to 120 min before a splenectomy (n = 8) or nephrectomy (n = 2), for the purpose of preventing a high intra- and post-operative blood loss and facilitating the technical procedure of removing an often markedly enlarged spleen. The operation time after balloon catheter occlusion was only 60-140 min; intra- and post-operative complications did not occur, other than one instance of pneumonia and one of subcutaneous haematoma. This method would seem to be suitable for reducing the operative risk of splenectomy or nephrectomy in the presence of a giant spleen or reduced tolerance of operation.

Adult↗
PubMed1989

Pros and cons of surgery of the left ventricular aneurysm--a review.

The prognosis for the patient with a left-ventricular aneurysm depends on the size of the aneurysm and the function of the remaining ventricle. Data in the literature suggest a 5-year-survival rate of 70-75% and a hospital mortality rate of 10% for aneurysmectomy with and without any additional aortocoronary bypass surgery. Medical treatment on the other hand is only credited with a markedly lower 5-year-survival rate of 45%. To date the only prospective data have been derived by the CASS Study, where no significant difference (67% for medical treatment, 69% for surgical treatment) was seen in the six-year-survival rate. However, considering only the patients with the combination of 3-vessel disease, coronary insufficiency, angina pectoris, and high age, the survival time after surgical treatment was significantly higher. The indication quoted for aneurysmectomy was angina pectoris in 46% of cases, acute or chronic coronary insufficiency in 33%, ventricular arrhythmias in 14%, and left ventricular thrombi in only 2.5%. The relative value of operative resection among the possible methods of treatment of the ventricular aneurysm is still a matter of controversy: there is a lack of larger-scale prospective studies comparing medical and surgical therapy.

Actuarial Analysis↗
PubMed1989

Will emergency coronary bypass grafting after failed elective percutaneous transluminal coronary angioplasty prevent myocardial infarction?

An emergency aorto-coronary bypass grafting operation was performed within 12 hours after the development of acute myocardial ischemia due to partial or complete vascular occlusion in 34 of 950 (3.6%) patients who had received elective percutaneous transluminal coronary angioplasty (PTCA). Of the 34 patients, three (= 8.8%) died postoperatively in irreversible cardiogenic shock. Half of the surviving patients developed a Q-wave infarction after the operation, whereas the other half remained without transmural infarct. With comparable clinical data and times of operation up to placement of the aorto-coronary bypass vessel, an adequate residual perfusion must still have been present in the cases with non Q-wave infarction. Since in many cases a myocardial necrosis is unavoidable despite relatively early operative revascularization, the decisive role will be played by the remaining perfusion of the vessel concerned and any collaterals. It follows that treatment of an early PTCA complication, occurring in the catheter laboratory, ought to be the earliest possible aorto-coronary bypass operation unless available cardiological methods can reliably assure reperfusion. Treatment of a PTCA complication occurring later, however, e.g. after hours in the intensive-care unit, should be a repeat PTCA attempt: surgery at this stage will not prevent the transmural infarction but will increase risk of lethal complications.

Adult↗